Chronic sialorrhea market to reach $1.02 billion by 2030
The chronic sialorrhea market is projected to grow from $0.76 billion in 2025 to $0.81 billion in 2026, with North America leading the market and Asia-Pacific expected to grow fastest. The Business Research Company points to rising neurodegenerative disease rates, R&D spending and new therapies as the main drivers.
Why it matters: - Chronic sialorrhea is tied to neurological diseases such as Parkinson’s disease, cerebral palsy and ALS, so market growth tracks a larger patient need. - Better treatment options could reduce complications like aspiration and improve oral function and quality of life for affected patients. - The market’s expansion also signals more spending on specialized care, devices and injectable therapies.
What happened: - The Business Research Company published its Chronic Sialorrhea Global Market Report 2026 with market sizing, trend and forecast data through 2035. - The report estimates the market will rise from $0.76 billion in 2025 to $0.81 billion in 2026, a 6.2% CAGR. - The report forecasts the market will reach $1.02 billion by 2030, at a 6.0% CAGR. - The report identifies North America as the largest regional market in 2025. - The report says Asia-Pacific will be the fastest-growing region over the forecast period. - Download a free sample of the report - View the full market report
The details: - Chronic sialorrhea is persistent overproduction or poor control of saliva. - Treatment options include pharmacological therapies, botulinum toxin injections and surgical interventions. - The report says growth over the historical period came from more neurological disorders, broader use of anticholinergic drugs, expansion of rehabilitation services, better diagnostics for salivary conditions and more specialty clinics. - The report points to approval of new injectable therapies, home care solutions, assistive oral devices, an aging population and rising investment in neurological disease management as future growth drivers. - The report highlights greater adoption of botulinum toxin treatments, more non-invasive therapies, more neurology-focused care and a stronger focus on patient quality of life as key trends. - The report says research and development is a major growth force because it supports better therapies, delivery methods and diagnostic tools. - The UK government raised net R&D spending to £17.4 billion ($22.1 billion) in 2023, up 8.2% from £16.1 billion ($20.45 billion) in 2022, according to the Office for National Statistics. - Parkinson’s UK said in September 2023 that about 153,000 people in the UK live with Parkinson’s disease, and that number is expected to rise 20% to around 172,000 by 2030. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.
Between the lines: - The forecast suggests chronic sialorrhea is moving from a niche treatment area toward a broader specialty market as more clinicians diagnose and manage the condition. - R&D spending and neurodegenerative disease prevalence give the market a structural growth base, not just a short-term spike. - The mix of botulinum toxin, non-invasive care and assistive devices points to a market where product competition is likely to center on convenience, efficacy and patient comfort.
What's next: - New injectable therapies could expand treatment options and support adoption through 2030. - Home care solutions and assistive oral devices are likely to gain more attention as care shifts outside specialist clinics. - Demand should continue rising as aging populations increase the number of patients living with Parkinson’s disease and other neurodegenerative disorders. - The Business Research Company says its expanded report tools are intended to help companies identify market hotspots and forecast demand more precisely.
The bottom line: - Chronic sialorrhea is a small but steadily growing market, with neurological disease trends and treatment innovation shaping the next phase of growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Science & Technology Watch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.